Cargando…

Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C

Background and Aims: Genotype (GT) 1 remains the predominant hepatitis c virus (HCV) GT in Chinese patients. Over 80% of those Chinese patients harbor the interferon-sensitive CC allele of IFNL4rs12979860, which is favorable for interferon-based treatment regimens. This phase III clinical trial aime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Lai, Shang, Jia, Ma, Yuanji, Xu, Xiaoyuan, Huang, Yan, Guan, Yujuan, Duan, Zhongping, Zhang, Wenhong, Gao, Zhiliang, Zhang, Mingxiang, Li, Jun, Jia, Jidong, Yang, Yongfeng, Wen, Xiaofeng, Wang, Maorong, Jia, Zhansheng, Ning, Bo, Chen, Yongping, Qi, Yue, Du, Jie, Jiang, Jianning, Tong, Lixin, Xie, Yao, Wu, Jinzi J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783684/ https://www.ncbi.nlm.nih.gov/pubmed/31608213 http://dx.doi.org/10.14218/JCTH.2019.00018

Ejemplares similares

Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
por: Xu, Xiaoyuan, et al.
Publicado: (2019)

First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients
por: Chen, Hongyi, et al.
Publicado: (2020)

Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy
por: Miao, Miao, et al.
Publicado: (2020)

Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
por: Rong, Libin, et al.
Publicado: (2013)

Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China
por: Pan, Shufang, et al.
Publicado: (2021)

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single‐arm, open‐label, phase 3 trial
por: Gao, Yanhang, et al.
Publicado: (2020)

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a
por: Chen, Xinyue, et al.
Publicado: (2019)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Consensus on the tertiary prevention of primary liver cancer
por: Nan, Yuemin, et al.
Publicado: (2023)

Correction to: Consensus on the secondary prevention of primary liver cancer
por: Nan, Yuemin, et al.
Publicado: (2022)

Consensus on the secondary prevention of primary liver cancer
por: Nan, Yuemin, et al.
Publicado: (2021)

A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B
por: Zhou, Jialing, et al.
Publicado: (2016)

Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)
por: You, Hong, et al.
Publicado: (2023)

HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study
por: Hu, Peng, et al.
Publicado: (2018)

Hepatitis C Virus Infection: Looking for Interferon Free Regimens
por: González-Moreno, J., et al.
Publicado: (2013)

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
por: Melotek, James M., et al.
Publicado: (2016)

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
por: Wei, Xin, et al.
Publicado: (2016)

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
por: Liu, Delong, et al.
Publicado: (2019)

CD100 Up-Regulation Induced by Interferon-α on B Cells Is Related to Hepatitis C Virus Infection
por: He, Yu, et al.
Publicado: (2014)

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
por: Tan, Qiu-Wen, et al.
Publicado: (2017)

Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)
por: You, Hong, et al.
Publicado: (2023)

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021)

Advances in the diagnosis and treatment of viral hepatitis B and C in China
por: Jia, Jidong
Publicado: (2022)

Infectious Bursal Disease Virus Influences the Transcription of Chicken γ(c) and γ(c) Family Cytokines during Infection
por: Wang, Sanying, et al.
Publicado: (2014)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

A mutation in the interferon regulatory element of HBV may influence the response of interferon treatment in chronic hepatitis B patients
por: Lu, Jia-Jie, et al.
Publicado: (2012)

Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis
por: Rao, Huiying, et al.
Publicado: (2020)

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
por: Lee, Matilda X., et al.
Publicado: (2018)

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023)

A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma
por: Xia, Yi, et al.
Publicado: (2017)

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer
por: Zhang, Qi, et al.
Publicado: (2017)

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma
por: Wang, Kailin, et al.
Publicado: (2019)

Twelve-Week Lower Trapezius-Centred Muscular Training Regimen in University Archers
por: Liao, Chien-Nan, et al.
Publicado: (2022)

Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation
por: Cholongitas, Evangelos, et al.
Publicado: (2017)

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Combination therapy based on pegylated interferon alfa improves the therapeutic response of patients with chronic hepatitis B who exhibit high levels of hepatitis B e-antigen at 24 weeks: A retrospective observational study
por: Zhang, Yafei, et al.
Publicado: (2019)

Phase II study of S‐1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off
por: Li, Jin, et al.
Publicado: (2017)

Media use and organ donation willingness: A latent profile analysis from Chinese residents
por: Gong, Fangmin, et al.
Publicado: (2022)

The clinical management of hepatocellular carcinoma in China: Progress and challenges
por: Shan, Shan, et al.
Publicado: (2023)

Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
por: Zhang, Fei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1se2foe33rt4f4celufto4tej6